Caribou Biosciences (CRBU) Competitors

$1.68 +0.06 (+3.40%)

As of 03:33 PM Eastern

CRBU vs. DRUG, GYRE, RGNX, MNPR, and AURA

Should you buy Caribou Biosciences stock or one of its competitors? MarketBeat compares Caribou Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Caribou Biosciences include Bright Minds Biosciences (DRUG), Gyre Therapeutics (GYRE), REGENXBIO (RGNX), Monopar Therapeutics (MNPR), and Aura Biosciences (AURA). These companies are all part of the "pharmaceutical products" industry.

How does Caribou Biosciences compare to Bright Minds Biosciences?

Bright Minds Biosciences (NASDAQ:DRUG) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

40.5% of Bright Minds Biosciences shares are owned by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are owned by institutional investors. 42.7% of Bright Minds Biosciences shares are owned by company insiders. Comparatively, 8.5% of Caribou Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Bright Minds Biosciences currently has a consensus price target of $143.83, indicating a potential upside of 85.24%. Caribou Biosciences has a consensus price target of $8.67, indicating a potential upside of 414.34%. Given Caribou Biosciences' higher probable upside, analysts clearly believe Caribou Biosciences is more favorable than Bright Minds Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bright Minds Biosciences	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Caribou Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Bright Minds Biosciences has higher earnings, but lower revenue than Caribou Biosciences. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.44	N/A
Caribou Biosciences	$11.16M	14.97	-$148.12M	-$1.42	N/A

In the previous week, Bright Minds Biosciences had 2 more articles in the media than Caribou Biosciences. MarketBeat recorded 2 mentions for Bright Minds Biosciences and 0 mentions for Caribou Biosciences. Bright Minds Biosciences' average media sentiment score of 0.77 beat Caribou Biosciences' score of 0.00 indicating that Bright Minds Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Bright Minds Biosciences	Positive
Caribou Biosciences	Neutral

Bright Minds Biosciences has a net margin of 0.00% compared to Caribou Biosciences' net margin of -1,189.14%. Bright Minds Biosciences' return on equity of -20.58% beat Caribou Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bright Minds Biosciences	N/A	-20.58%	-20.25%
Caribou Biosciences	-1,189.14%	-84.17%	-60.51%

Bright Minds Biosciences has a beta of -5.34, indicating that its stock price is 634% less volatile than the broader market. Comparatively, Caribou Biosciences has a beta of 2.36, indicating that its stock price is 136% more volatile than the broader market.

Summary

Bright Minds Biosciences beats Caribou Biosciences on 9 of the 16 factors compared between the two stocks.

How does Caribou Biosciences compare to Gyre Therapeutics?

Gyre Therapeutics (NASDAQ:GYRE) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

Gyre Therapeutics has higher revenue and earnings than Caribou Biosciences. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gyre Therapeutics	$117.05M	5.78	$5.03M	-$0.09	N/A
Caribou Biosciences	$11.16M	14.97	-$148.12M	-$1.42	N/A

Gyre Therapeutics has a beta of 1.89, suggesting that its stock price is 89% more volatile than the broader market. Comparatively, Caribou Biosciences has a beta of 2.36, suggesting that its stock price is 136% more volatile than the broader market.

Gyre Therapeutics presently has a consensus target price of $17.00, suggesting a potential upside of 180.07%. Caribou Biosciences has a consensus target price of $8.67, suggesting a potential upside of 414.34%. Given Caribou Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Caribou Biosciences is more favorable than Gyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Caribou Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Gyre Therapeutics had 1 more articles in the media than Caribou Biosciences. MarketBeat recorded 1 mentions for Gyre Therapeutics and 0 mentions for Caribou Biosciences. Gyre Therapeutics' average media sentiment score of 0.00 equaled Caribou Biosciences'average media sentiment score.

Company	Overall Sentiment
Gyre Therapeutics	Neutral
Caribou Biosciences	Neutral

24.0% of Gyre Therapeutics shares are held by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are held by institutional investors. 9.5% of Gyre Therapeutics shares are held by insiders. Comparatively, 8.5% of Caribou Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Gyre Therapeutics has a net margin of -5.44% compared to Caribou Biosciences' net margin of -1,189.14%. Gyre Therapeutics' return on equity of 3.13% beat Caribou Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gyre Therapeutics	-5.44%	3.13%	2.67%
Caribou Biosciences	-1,189.14%	-84.17%	-60.51%

Summary

Gyre Therapeutics beats Caribou Biosciences on 8 of the 15 factors compared between the two stocks.

How does Caribou Biosciences compare to REGENXBIO?

Caribou Biosciences (NASDAQ:CRBU) and REGENXBIO (NASDAQ:RGNX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, media sentiment and dividends.

Caribou Biosciences currently has a consensus price target of $8.67, indicating a potential upside of 414.34%. REGENXBIO has a consensus price target of $23.82, indicating a potential upside of 132.35%. Given Caribou Biosciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Caribou Biosciences is more favorable than REGENXBIO.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caribou Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
REGENXBIO	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.62

Caribou Biosciences has higher earnings, but lower revenue than REGENXBIO. REGENXBIO is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caribou Biosciences	$11.16M	14.97	-$148.12M	-$1.42	N/A
REGENXBIO	$87.82M	6.03	-$193.88M	-$5.60	N/A

In the previous week, REGENXBIO had 10 more articles in the media than Caribou Biosciences. MarketBeat recorded 10 mentions for REGENXBIO and 0 mentions for Caribou Biosciences. REGENXBIO's average media sentiment score of 0.21 beat Caribou Biosciences' score of 0.00 indicating that REGENXBIO is being referred to more favorably in the news media.

Company	Overall Sentiment
Caribou Biosciences	Neutral
REGENXBIO	Neutral

77.5% of Caribou Biosciences shares are held by institutional investors. Comparatively, 88.1% of REGENXBIO shares are held by institutional investors. 8.5% of Caribou Biosciences shares are held by insiders. Comparatively, 14.2% of REGENXBIO shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Caribou Biosciences has a beta of 2.36, suggesting that its stock price is 136% more volatile than the broader market. Comparatively, REGENXBIO has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market.

REGENXBIO has a net margin of -330.23% compared to Caribou Biosciences' net margin of -1,189.14%. Caribou Biosciences' return on equity of -84.17% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Caribou Biosciences	-1,189.14%	-84.17%	-60.51%
REGENXBIO	-330.23%	-232.50%	-61.02%

Summary

Caribou Biosciences beats REGENXBIO on 10 of the 17 factors compared between the two stocks.

How does Caribou Biosciences compare to Monopar Therapeutics?

Monopar Therapeutics (NASDAQ:MNPR) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

Monopar Therapeutics has a net margin of 0.00% compared to Caribou Biosciences' net margin of -1,189.14%. Monopar Therapeutics' return on equity of -12.84% beat Caribou Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monopar Therapeutics	N/A	-12.84%	-12.57%
Caribou Biosciences	-1,189.14%	-84.17%	-60.51%

Monopar Therapeutics presently has a consensus price target of $108.75, indicating a potential downside of 0.58%. Caribou Biosciences has a consensus price target of $8.67, indicating a potential upside of 414.34%. Given Caribou Biosciences' higher probable upside, analysts plainly believe Caribou Biosciences is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monopar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07
Caribou Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Monopar Therapeutics had 6 more articles in the media than Caribou Biosciences. MarketBeat recorded 6 mentions for Monopar Therapeutics and 0 mentions for Caribou Biosciences. Monopar Therapeutics' average media sentiment score of 0.65 beat Caribou Biosciences' score of 0.00 indicating that Monopar Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Monopar Therapeutics	Positive
Caribou Biosciences	Neutral

1.8% of Monopar Therapeutics shares are owned by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are owned by institutional investors. 9.7% of Monopar Therapeutics shares are owned by company insiders. Comparatively, 8.5% of Caribou Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Monopar Therapeutics has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market. Comparatively, Caribou Biosciences has a beta of 2.36, suggesting that its stock price is 136% more volatile than the broader market.

Monopar Therapeutics has higher earnings, but lower revenue than Caribou Biosciences. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monopar Therapeutics	N/A	N/A	-$13.72M	-$1.90	N/A
Caribou Biosciences	$11.16M	14.97	-$148.12M	-$1.42	N/A

Summary

Monopar Therapeutics beats Caribou Biosciences on 10 of the 16 factors compared between the two stocks.

How does Caribou Biosciences compare to Aura Biosciences?

Aura Biosciences (NASDAQ:AURA) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.

Aura Biosciences has a net margin of 0.00% compared to Caribou Biosciences' net margin of -1,189.14%. Aura Biosciences' return on equity of -78.12% beat Caribou Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aura Biosciences	N/A	-78.12%	-64.08%
Caribou Biosciences	-1,189.14%	-84.17%	-60.51%

96.8% of Aura Biosciences shares are owned by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are owned by institutional investors. 1.9% of Aura Biosciences shares are owned by company insiders. Comparatively, 8.5% of Caribou Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Aura Biosciences has a beta of 0.4, indicating that its stock price is 60% less volatile than the broader market. Comparatively, Caribou Biosciences has a beta of 2.36, indicating that its stock price is 136% more volatile than the broader market.

Aura Biosciences has higher earnings, but lower revenue than Caribou Biosciences. Aura Biosciences is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A
Caribou Biosciences	$11.16M	14.97	-$148.12M	-$1.42	N/A

In the previous week, Aura Biosciences' average media sentiment score of 0.00 equaled Caribou Biosciences'average media sentiment score.

Company	Overall Sentiment
Aura Biosciences	Neutral
Caribou Biosciences	Neutral

Aura Biosciences currently has a consensus price target of $20.50, indicating a potential upside of 193.28%. Caribou Biosciences has a consensus price target of $8.67, indicating a potential upside of 414.34%. Given Caribou Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Caribou Biosciences is more favorable than Aura Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Caribou Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Caribou Biosciences beats Aura Biosciences on 9 of the 13 factors compared between the two stocks.

Get Caribou Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRBU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRBU vs. The Competition

Export

Metric	Caribou Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$166.13M	$3.65B	$6.80B	$12.44B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-1.18	20.66	27.00	24.19
Price / Sales	14.97	322.67	518.66	94.29
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	1.29	8.17	10.68	6.26
Net Income	-$148.12M	$23.81M	$3.59B	$331.52M
7 Day Performance	-3.71%	-1.53%	-0.19%	-1.19%
1 Month Performance	3.06%	2.21%	1.93%	-1.35%
1 Year Performance	-18.60%	44.90%	25.24%	18.74%

Caribou Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRBU Caribou Biosciences	1.7321 of 5 stars	$1.68 +3.4%	$8.67 +417.4%	-21.0%	$166.13M	$11.16M	N/A	100
DRUG Bright Minds Biosciences	2.5099 of 5 stars	$75.93 -2.5%	$143.83 +89.4%	+185.2%	$757.55M	N/A	N/A	N/A
GYRE Gyre Therapeutics	1.6859 of 5 stars	$6.34 -2.8%	$17.00 +168.1%	-18.4%	$726.91M	$116.59M	N/A	40	Positive News
RGNX REGENXBIO	3.6379 of 5 stars	$12.75 -8.6%	$23.82 +86.8%	+26.5%	$721.18M	$170.44M	N/A	370	Gap Down
MNPR Monopar Therapeutics	1.311 of 5 stars	$103.33 -3.1%	$108.75 +5.2%	+127.8%	$714.12M	N/A	N/A	10	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRBU) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Caribou Biosciences (CRBU) Competitors

CRBU vs. DRUG, GYRE, RGNX, MNPR, and AURA

How does Caribou Biosciences compare to Bright Minds Biosciences?

Summary

How does Caribou Biosciences compare to Gyre Therapeutics?

Summary

How does Caribou Biosciences compare to REGENXBIO?

Summary

How does Caribou Biosciences compare to Monopar Therapeutics?

Summary

How does Caribou Biosciences compare to Aura Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRBU vs. The Competition

Caribou Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Caribou Biosciences (CRBU) Competitors

CRBU vs. DRUG, GYRE, RGNX, MNPR, and AURA

How does Caribou Biosciences compare to Bright Minds Biosciences?

Do insiders & institutionals believe in DRUG or CRBU?

Do analysts recommend DRUG or CRBU?

Which has better earnings & valuation, DRUG or CRBU?

Does the media prefer DRUG or CRBU?

Is DRUG or CRBU more profitable?

Which has more volatility & risk, DRUG or CRBU?

Summary

How does Caribou Biosciences compare to Gyre Therapeutics?

Which has preferable earnings and valuation, GYRE or CRBU?

Which has more risk and volatility, GYRE or CRBU?

Do analysts rate GYRE or CRBU?

Does the media refer more to GYRE or CRBU?

Do insiders & institutionals have more ownership in GYRE or CRBU?

Is GYRE or CRBU more profitable?

Summary

How does Caribou Biosciences compare to REGENXBIO?

Do analysts prefer CRBU or RGNX?

Which has stronger valuation and earnings, CRBU or RGNX?

Does the media favor CRBU or RGNX?

Do insiders and institutionals believe in CRBU or RGNX?

Which has more volatility & risk, CRBU or RGNX?

Is CRBU or RGNX more profitable?

Summary

How does Caribou Biosciences compare to Monopar Therapeutics?

Is MNPR or CRBU more profitable?

Do analysts rate MNPR or CRBU?

Does the media refer more to MNPR or CRBU?

Do institutionals and insiders believe in MNPR or CRBU?

Which has more risk and volatility, MNPR or CRBU?

Which has preferable valuation and earnings, MNPR or CRBU?

Summary

How does Caribou Biosciences compare to Aura Biosciences?

Is AURA or CRBU more profitable?

Do institutionals & insiders hold more shares of AURA or CRBU?

Which has more risk and volatility, AURA or CRBU?

Which has higher valuation & earnings, AURA or CRBU?

Does the media prefer AURA or CRBU?

Do analysts prefer AURA or CRBU?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRBU vs. The Competition

Caribou Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools